All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
While the larger market has slowed, venture capital (VC) financing continues with two new funds, one from 35-year-old Canaan Partners and one from newbie Cure Ventures. The 13th fund from Canaan contains $850 million in new capital, including an oversubscribed $650 million fund intended for seed and series A funding. Cure Ventures launched its inaugural fund with $350 million in capital commitments.
Mercy Bioanalytics Inc. stepped into the increasingly competitive early cancer detection field with a $41 million series A financing round to support its Halo liquid biopsy platform. Novalis Lifesciences led the oversubscribed round with participation from Sozo Ventures, Hatteras Venture Partners, Iselect Fund, American Cancer Society BrightEdge and Broadway Angels, an all-women venture capital group. Laboratory Corp. of America Holdings, Bruker Corp. and existing investors also contributed to the round.
Adcendo ApS has added a further €31 million (US$33.6 million) to its series A round, providing the means to take its lead antibody-drug conjugate (ADC) through to clinical proof of concept in the treatment of sarcoma.